Finance

Lists
Why is AGMB down ५.७९%?
Dive Deeper
AGMB:NASDAQ
Agomab Therapeutics NV
US$ ७.४९
-५.७९%
(-०.४६) 1D
अक्टोबर ३०, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGMB...
Open
US$ ७.००
High
US$ ७.९६
Low
US$ ६.६१
Mkt. cap
३६.८९ करोड
Avg. vol.
१.४२ लाख
Volume
१.९८ लाख
52-wk high
US$ १७.८२
52-wk low
US$ ६.६१
No. of employees
६२
Open
US$ ७.००
High
US$ ७.९६
Low
US$ ६.६१
Mkt. cap
३६.८९ करोड
Avg. vol.
१.४२ लाख
Volume
१.९८ लाख
52-wk high
US$ १७.८२
52-wk low
US$ ६.६१
No. of employees
६२
News stories
From web sources and news partners
shattered.io
shattered.io
·
४२ मिनेट पहिले
Anthropic IPO Valuation Slips to $1.5T From $2T [2026]
Yahoo Finance
Yahoo Finance
·
१४ घण्टा पहिले
Tom Lee Thinks One Investor Might Be Behind Nasdaq’s Stock Crash
CNBC
CNBC
·
१७ घण्टा पहिले
Anthropic's path to the Nasdaq just got a lot bumpier
About Agomab Therapeutics NV
CEO-
Employees६२
Founded२०१७
Headquarters-
Sector-
Websiteagomab.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGMB in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGMB in the last 3 months.
Highest
Current US$ ७.४९
US$ ६०.०० (+७०१.०७%)
Average
US$ ३५.२० (+३६९.९६%)
Lowest
US$ १७.०० (+१२६.९७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Buy
Reiterated
US$ २८.००
+२७३.८%
10/26/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
US$ ३५.००
+३६७.३%
10/20/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$ २८.००
+२७३.८%
10/19/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$ ६०.००
+७०१.१%
10/14/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
US$ ३६.००
+३८०.६%
10/02/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
09/14/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
US$ १७.००
+१२७%
08/19/2026
William Wood
B. Riley Securities
Buy
Initiated
US$ ३४.००
+३५३.९%
07/23/2026
Thomas Smith
Leerink Partners
Buy
Initiated
US$ ३६.००
+३८०.६%
03/03/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
२०२५ जुन
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.१० करोड
१.३९ करोड
१.१५ करोड
१.१५ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३३.४१ लाख
३१.७१ लाख
६०.८६ लाख
६०.८६ लाख
Operating expense
१.३७ करोड
१.६५ करोड
१.७० करोड
१.७० करोड
Total operating expenses
१.३७ करोड
१.६५ करोड
१.७० करोड
१.७० करोड
Operating income
-१.३७ करोड
-१.६५ करोड
-१.७० करोड
-१.७० करोड
Other non operating income
-१.२८ लाख
-१५.३७ लाख
-२.१९ लाख
-२.१९ लाख
EBT including unusual items
-१.३४ करोड
-१.७४ करोड
-१.५५ करोड
-१.५५ करोड
EBT excluding unusual items
-१.३४ करोड
-१.७४ करोड
-१.५५ करोड
-१.५५ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-६.५६ लाख
-५.०६ लाख
-५.४० लाख
-५.४० लाख
Net income
-१.३४ करोड
-१.७४ करोड
-१.५५ करोड
-१.५५ करोड
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
४.२८ लाख
७.२० लाख
१८.७० लाख
१८.७० लाख
Interest expense
-३७.५० हजार
-
-१.०८ लाख
-१.०८ लाख
Net interest expenses
३.९० लाख
७.२० लाख
१७.६३ लाख
१७.६३ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.३६ करोड
-१.६५ करोड
-१.६९ करोड
-१.६९ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू